EMA expects Johnson & Johnson to file for vaccine approval within days New BioNTech production site will have capacity to produce 750m doses annually
Fri, Feb 12, 2021, 17:04 Updated: Fri, Feb 12, 2021, 21:26
The first stage of BioNTech’s vaccine process, producing the active ingredient known as mRNA, has begun at a new plant in Marburg. Photograph: AFP via Getty
The European Medicines Agency (EMA) expects Johnson & Johnson to file for approval of its Covid-19vaccine in the EU within the next few days. Approval of this inoculation is viewed by many as pivotal in speeding up the overall rollout of vaccines, in part because it may only require one dose.